Rheumatic Disease eJournal Club
American College of Rheumatology
2008 Recommendations
for the Use
of Nonbiologic and Biologic Disease-Modifying
Antirheumatic Drugs in Rheumatoid Arthritis
Publication: Saag K et al. Arthritis Rheum. 2008;59:762-784.
Release Date: October 3, 2008
Renewal Date: October 5, 2009
Expiration Date: October 5, 2010
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Estimated Time of Completion: 45 minutes
Description
The purpose of this activity is to review the 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic DMARDs in rheumatoid arthritis.
Objectives
On completion of this activity, participants should be able to:
- Design monotherapy and combination DMARD therapies.
- Outline recommendations on use of anti-TNFα agents in patients with early and longer-duration RA.
- Discuss the screening and monitoring procedures for nonbiologic and biologic DMARDs.
Target Audience
This activity is directed to physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in RA.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Faculty
Kenneth Saag, MD, MSc
Associate Professor of Medicine
Division of Clinical Immunology and Rheumatology
University of Alabama
Birmingham, Alabama
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO | ||
| Consulting: | Abbott Laboratories; Genentech, Inc.; Roche Laboratories, Inc. | |
| Teaching and Speaking: | Genentech, Inc. | |
| Kenneth Saag, MD, MSc | ||
| Consulting: | Amgen Inc.; Eli Lilly and Company; Merck & Co., Inc; Nitec Pharma AG; Novartis AG; Roche Laboratories, Inc.; UCB | |
| Teaching and Speaking: | Eli Lilly and Company; Merck & Co., Inc. | |
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:
Roche Laboratories, Inc.
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME .
